Accessibility Menu
Ensysce Biosciences logo

Ensysce Biosciences(NASDAQ) ENSC

Current Price$0.26
Market Cap$4.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-100%
1 Year-88%
1 Month-7%
Ensysce Biosciences last closing stock price
MetricPriceDate
Last closeUSD 0.262026-07-24
Ensysce Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.57%USD 0.282026-07-17
1 month-6.64%USD 0.282026-06-24
3 month-36.89%USD 0.412026-04-24
Year to date-71.59%USD 0.922025-12-31
1 year-88.12%USD 2.202025-07-24
3 year-99.19%USD 32.102023-07-25
5 year-100%USD 25,199.642021-07-23
Since inception-100%USD 34,740.002018-02-26

Ensysce Biosciences Financials at a Glance

Market Cap

$4.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.45M

Net Income (TTM)

-$11.79M

EPS (TTM)

-$3.35

P/E Ratio

-0.08

Dividend

$0.00

Beta (Volatility)

0.95 (Low)

Price

$0.26

Volume

7,558

Open

$0.27

Previous Close

$0.26

Daily Range

$0.26 - $0.27

52-Week Range

$0.23 - $2.75

Estimated Earnings Date

Aug 12, 2026

ENSC News

Foolcom-Featured.png

Ensysce Biosciences Narrows Loss in Q2

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ensysce Biosciences

Ensysce develops new prescription drugs to help prevent opioid misuse and overdose. Its products aim to make pain relief safer for patients and healthcare providers. The company’s technology targets people needing strong pain relief while reducing risks of addiction and overdose.

Pills With a Purpose: What Ensysce Makes

  • TAAP Platform: Abuse-resistant opioid drugs for pain relief; 100% of revenue comes from federal grants supporting abuse-deterrent technology development.
  • MPAR Platform: Overdose protection technology for opioid medications; in 2025, all recognized revenue was from related federal grants.
  • PF614: Oxycodone-based pain medication in late-stage clinical trials, designed to deter misuse.
  • PF614-MPAR: Combination product for overdose protection, in early clinical testing.
  • Nafamostat: Drug candidate for lung diseases and viral infections, completed initial safety trials.

Growth Spurts and Strategic Moves

  • Signed a product development and supply agreement with Galephar Pharmaceutical Research in January 2025.
  • Secured a new multi-year federal grant from NIH/NIDA in August 2024, totaling $15.1 million through 2027.
  • PF614 is in Phase 3 clinical development and PF614-MPAR is in Phase 1b clinical development in 2025.
  • Raised capital through multiple equity and warrant offerings in 2024 and 2025.
  • Expanded research into treatments for coronavirus and pulmonary diseases via subsidiary EBIR, Inc.

What Makes Ensysce Stand Out in the Crowd

Ensysce’s technology focuses on making opioid medications harder to misuse and safer in overdose situations. The company relies on federal grants and partnerships for research and development. Its small team works with outside organizations for manufacturing and clinical trials.

Five Things You Need to Know

  • Revenue was $1.0 million in Q2 2025, up 654.4% from Q2 2024.
  • All revenue comes from federal grants; no product sales as of June 2025.
  • Operating loss was $1.75 million in Q2 2025, improving 10.5% year-over-year.
  • Cash and equivalents were $2.21 million as of June 30, 2025.
  • Ensysce had 7 full-time employees and $9.4 million in grant funding remaining in June 2025.

Bottom Line

Ensysce is a small biotech focused on safer pain medications, funded mainly by federal grants. Its future depends on clinical progress and continued access to capital.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

10

CEO

D. Lynn Kirkpatrick, PhD

Website

www.ensysce.com

Headquarters

La Jolla, CA 92037, US

ENSC Financials

Key Financial Metrics (TTM)

Gross Margin

-103.66%

Operating Margin

-813.95%

Net Income Margin

-810.57%

Return on Equity

-631.47%

Return on Capital

-0.00%

Return on Assets

-543.71%

Earnings Yield

-12.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

15.37M

Volume

7.56K

Avg. Volume

2.56M

Financials (TTM)

Gross Profit

-$1.51M

Operating Income

-$11.84M

EBITDA

-$8.04M

Operating Cash Flow

-$9.60M

Capital Expenditure

-$123.64K

Free Cash Flow

-$9.72M

Cash & ST Invst.

$745.48K

Total Debt

$245.85K

Ensysce Biosciences Performance Analysis

Ensysce Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,523,383-28.5%
20232023-12-31USD 2,230,520-11.6%
20242024-12-31USD 5,210,031133.6%
20252025-12-31USD 5,066,650-2.8%
Ensysce Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-100.0%
Q32025-09-30N/A
Q42025-12-31-100.0%
Q12026-03-31N/A
Ensysce Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2,091.24-60.8%
20232023-12-31USD -70.40-96.6%
20242024-12-31USD -11.45-83.7%
20252025-12-31USD -3.98-65.2%
Ensysce Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3043.2%
Q32025-09-30-63.3%
Q42025-12-3160.5%
Q12026-03-31-2.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$961.00K

-27.2%

Gross Profit

$954.47K

-27.7%

Gross Margin

99.32%

N/A

Market Cap

$4.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$573.79K

N/A

Employees

7

N/A

Net Income

-$3.56M

-82.8%

EBITDA

-$3.56M

-83.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$745.48K

-75.6%

Total Debt

$245.85K

-4.5%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$245.85K

-4.5%

Return on Assets

-5.44%

N/A

Return on Invested Capital

17.69%

N/A

Free Cash Flow

-$3.50M

-105.0%

Operating Cash Flow

-$3.50M

-105.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TTNPTitan Pharmaceuticals, Inc.
$2.34-11.36%
XBIOXenetic Biosciences, Inc.
$2.64-1.68%
QLGNQualigen Therapeutics, Inc.
$3.21+5.59%
SNGXSoligenix, Inc.
$0.37+0.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
FFord Motor Company
$14.37+0.02%
AALAmerican Airlines Group
$14.48+0.07%

Questions About ENSC

What is the current price of Ensysce Biosciences?

Ensysce Biosciences is trading at $0.26 per share.

What is the 52-week range for Ensysce Biosciences?

Over the past 52 weeks, Ensysce Biosciences has traded between $0.23 and $2.75.

How much debt does Ensysce Biosciences have?

As of the most recent reporting period, Ensysce Biosciences reported total debt of $216.00K.

How much cash does Ensysce Biosciences have on hand?

Ensysce Biosciences reported $745.48K in cash and cash equivalents in its most recent financial results.

What is Ensysce Biosciences’s dividend yield?

Ensysce Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services